[#item_full_content] The Food and Drug Administration (FDA) is seeking public input on how to design research on the potential therapeutic benefits of the psychedelic ibogaine. The agency’s request for information (RFI), released on Monday, seeks comments and data in four main areas: General study design, including appropriate patient populations; Dose selection and escalation, including the proposed 
Read More
